Insider Selling: Calumet (NASDAQ:CLMT) Director Sells 20,000 Shares of Stock

Calumet, Inc. (NASDAQ:CLMT) Director Daniel Sajkowski sold 20,000 shares of the company’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $12.55, for a total value of $251,000.00. Following the transaction, the director directly owned 121,959 shares in the company, valued at $1,530,585.45. The trade was a 14.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Calumet Trading Up 2.1%

NASDAQ:CLMT traded up $0.63 on Thursday, hitting $30.22. 1,721,709 shares of the company’s stock traded hands, compared to its average volume of 1,367,486. The company has a market cap of $2.62 billion, a PE ratio of -70.28 and a beta of 1.24. Calumet, Inc. has a 1 year low of $7.68 and a 1 year high of $30.35. The firm has a 50-day moving average price of $22.92 and a 200-day moving average price of $19.82.

Institutional Trading of Calumet

Several large investors have recently made changes to their positions in CLMT. Islay Capital Management LLC acquired a new position in shares of Calumet during the 4th quarter valued at about $25,000. Aster Capital Management DIFC Ltd boosted its position in Calumet by 294.7% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 1,646 shares of the oil and gas company’s stock worth $33,000 after purchasing an additional 1,229 shares during the period. Global Retirement Partners LLC acquired a new position in Calumet during the fourth quarter valued at approximately $34,000. Amalgamated Bank acquired a new position in Calumet during the second quarter valued at approximately $37,000. Finally, Covestor Ltd raised its position in shares of Calumet by 29.1% in the fourth quarter. Covestor Ltd now owns 2,180 shares of the oil and gas company’s stock valued at $43,000 after purchasing an additional 492 shares during the period. Institutional investors own 34.41% of the company’s stock.

Analyst Ratings Changes

CLMT has been the topic of a number of research reports. The Goldman Sachs Group upped their price target on shares of Calumet from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. TD Cowen restated a “hold” rating on shares of Calumet in a research note on Thursday, January 29th. UBS Group reaffirmed a “neutral” rating and set a $26.00 price target on shares of Calumet in a research note on Friday, February 13th. HC Wainwright reiterated a “buy” rating and set a $33.00 price target on shares of Calumet in a report on Monday, November 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Calumet in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $22.83.

About Calumet

Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) is an independent provider of high-value, essential product solutions derived from both petroleum and renewable feedstocks. The company operates an integrated network of manufacturing plants, blending terminals and storage facilities across North America, delivering customized products and technical services to industrial, automotive, consumer and agricultural end markets. By leveraging its scale and technical expertise, Calumet tailors supply chain and formulation solutions to meet stringent regulatory and performance requirements.

Calumet’s product portfolio includes specialty lubricants and base oils for high-performance applications; process oils and waxes for food-grade, cosmetic and packaging uses; industrial solvents and cleaning solutions; and fuel additives designed to optimize engine performance and emissions.